NCT01202591 - Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions

FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer

Interventions

DRUG

AZD4547

Tablet oral twice daily

DRUG

Exemestane

Tablet oral once daily

DRUG

Placebo

Tablet oral twice daily

DRUG

Fulvestrant

A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration

Trial Locations (21)

Research Site, Leuven

Research Site, Namur

Research Site, Brno

Research Site, Prague

Research Site, Villejuif

Research Site, Erlangen

Research Site, München

Research Site, Rostock

Research Site, Budapest

Research Site, Kaposvár

Research Site, Nyíregyháza

Research Site, Szeged

Research Site, Genova

Research Site, Lido di Camaiore

Research Site, Roma

Research Site, Cluj-Napoca

Research Site, Dundee

Research Site, London

Research Site, Manchester

Research Site, Oxford

Research Site, Sutton